AIP
INKT icon

Ameritas Investment Partners’s MiNK Therapeutics INKT Stock Holding History

Ameritas Investment Partners’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15
Closed – – 3149
2022
Q1 		$0 Hold
15
– – ﹤0.01% 3088
2021
Q4 		$1K Buy
+15
New +$1.78K ﹤0.01% 3102

Other funds holding INKT

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameritas Investment Partners's INKT Position: Q2 2022 in Review

Ameritas Investment Partners sold out of MiNK Therapeutics (INKT) in Q2 2022, closing a stake of 15 shares.

Ameritas Investment Partners first reported a position in INKT in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 11 funds tracked by Wall St. Rank hold INKT as of Q2 2022.

  • Ameritas Investment Partners reported no remaining MiNK Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 15 MiNK Therapeutics shares in Q2 2022.
  • Ameritas Investment Partners first reported a position in MiNK Therapeutics in Q4 2021 and held it in 2 quarters.
  • Ameritas Investment Partners's MiNK Therapeutics position peaked at $1K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.